<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072124</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000335471</org_study_id>
    <secondary_id>NCI-03-C-0279</secondary_id>
    <nct_id>NCT00072124</nct_id>
    <nct_alias>NCT00068939</nct_alias>
  </id_info>
  <brief_title>Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>A Prospective Random Assignment Trial Comparing Complete Metastasectomy to Chemotherapy for Selected Patients With Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Complete metastasectomy&#xD;
      may be an effective treatment for metastatic melanoma and may improve quality of life and&#xD;
      help patients live longer and more comfortably. It is not yet known whether complete&#xD;
      metastasectomy is more effective than chemotherapy in treating stage IV melanoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying dacarbazine and/or cisplatin to see how&#xD;
      well they work compared to complete metastasectomy in treating patients with stage IV&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare overall survival in patients with stage IV melanoma treated with complete&#xD;
           metastasectomy vs dacarbazine and/or cisplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare time to progression in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the response rate in patients treated with dacarbazine and/or cisplatin.&#xD;
&#xD;
        -  Compare the morbidity and quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to prior exposure to&#xD;
      dacarbazine and cisplatin (yes vs no) and number of sites of metastases (1 vs 2 or more).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (surgery): Patients undergo complete metastasectomy. Patients with disease&#xD;
           progression after surgery may undergo repeat resection or may receive dacarbazine and/or&#xD;
           cisplatin as in arm II.&#xD;
&#xD;
        -  Arm II (systemic therapy): Patients receive dacarbazine IV over 30-60 minutes and/or&#xD;
           cisplatin IV over 30 minutes on days 1, 2, 3, 22, 23, and 24 (1 course). Courses repeat&#xD;
           every 42 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
           achieving a complete response (CR) receive at least 1 additional course of chemotherapy&#xD;
           beyond CR and are eligible for other investigational strategies.&#xD;
&#xD;
      Quality of life is assessed at baseline, at 3 and 6 months, and at 1 year.&#xD;
&#xD;
      Patients are followed every 3-4 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 74 patients (37 per treatment arm) will be accrued for this&#xD;
      study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma&#xD;
&#xD;
               -  Solitary pulmonary nodule may not be sole site of metastatic disease&#xD;
&#xD;
               -  No disease limited to subcutaneous, cutaneous, or peripheral nodal (neck,&#xD;
                  axillary, groin, or iliac nodes) sites only&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Disease progression during or after prior interleukin-2 (IL-2)-based therapy OR&#xD;
             ineligible for high-dose IL-2 therapy&#xD;
&#xD;
          -  Metastatic disease amenable to complete surgical resection&#xD;
&#xD;
               -  Less than 5% estimated mortality from surgery&#xD;
&#xD;
               -  Prior complete metastasectomy allowed provided disease did not recur within 6&#xD;
                  months after surgery&#xD;
&#xD;
          -  No primary ocular or mucosal melanoma&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3 OR&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
          -  No major medical illness of the renal system&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No major medical illness of the cardiovascular system&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No major medical illness of the respiratory system&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No form of primary or secondary immunodeficiency&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent palliative surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior therapy for melanoma (except surgery)&#xD;
&#xD;
          -  No other concurrent therapy for melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M. Sherry, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

